Moreover, adoptively transferred ILC2 treatment can be developed in combination with other anti-cancer therapeutic approaches, such as in combination with immune checkpoint blockade therapies (biologics against PD-1, CTLA-4 or OX40), cytokines such as IL-33, or radio- and chemotherapies to enhance the outcomes. This evidence concerns the gene IL33 and cancer.